Evidence map›Paper›PMID 33858442›Full record

ReviewLipids in health and disease2021

Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region.

Zhen-Vin Lee, Elmer Jasper Llanes, Renan Sukmawan, Nuntakorn Thongtang, Huynh Quang Tri Ho, Philip Barter, Cardiovascular RISk Prevention (CRISP) in Asia Network

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Lipids in health and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Lipid Metabolism Modulation by a Flavonoid-StandardizedJournal of experimental pharmacology · 2026
    Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 5 countries.

Zhen-Vin LeeUniversity Malaya Medical Centre, Kuala Lumpur, Malaysia.
Elmer Jasper LlanesDivision of Cardiovascular Medicine, University of the Philippines, Manila, Philippines.
Renan SukmawanDepartment of Cardiology & Vascular Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.
Nuntakorn ThongtangDivision of Endocrinology and Metabolism, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok, Thailand.
Huynh Quang Tri HoHeart Institute, Ho Chi Minh City, Vietnam.
Philip BarterSchool of Medical Sciences, University of New South Wales, Sydney, NSW, Australia. pbarter@ozemail.com.au.
Cardiovascular RISk Prevention (CRISP) in Asia Network
National Brain Centre · IDSiriraj Hospital · THUniversity Malaya Medical Centre · MYUniversity of the Philippines Manila · PHUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) is a major cause of mortality and morbidity within the Asia-Pacific region, with the prevalence of CVD risk factors such as plasma lipid disorders increasing in many Asian countries. As members of the Cardiovascular RISk Prevention (CRISP) in Asia network, the authors have focused on plasma lipid disorders in the six countries within which they have clinical experience: Indonesia, Malaysia, Philippines, Thailand, Vietnam, and Australia. Based on country-specific national surveys, the prevalence of abnormal levels of total cholesterol, low- and high-density lipoprotein cholesterol (LDL-C and HDL-C, respectively), and triglycerides (TG) are reported. An important caveat is that countries have used different thresholds to define plasma lipid disorders, making direct comparisons difficult. The prevalence of abnormal lipid levels was as follows: high total cholesterol (30.2-47.7%, thresholds: 190-213 mg/dL); high LDL-C (33.2-47.5%; thresholds: 130-135 mg/dL); low/abnormal HDL-C (22.9-72.0%; thresholds: 39-50 mg/dL); and high/abnormal TG (13.9-38.7%; thresholds: 150-177 mg/dL). Similarities and differences between country-specific guidelines for the management of plasma lipid disorders are highlighted. Based on the authors' clinical experience, some of the possible reasons for suboptimal management of plasma lipid disorders in each country are described. Issues common to several countries include physician reluctance to prescribe high-dose and/or high-intensity statins and poor understanding of disease, treatments, and side effects among patients. Treatment costs and geographical constraints have also hampered disease management in Indonesia and the Philippines. Understanding the factors governing the prevalence of plasma lipid disorders helps enhance strategies to reduce the burden of CVD in the Asia-Pacific region.

Indexed as

AsiaCholesterol, LDLHumansHypolipidemic AgentsLipid Metabolism DisordersPacific OceanPractice Guidelines as TopicPrevalenceCholesterol, LDLHypolipidemic AgentsAsia-PacificDyslipidemiaGuidelinesPlasma lipid disordersPrevalence

Identifiers

PMID33858442
PMCPMC8051043
OpenAlexW3153311054

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.